Menorrhagia is a common clinical problem and is unexplained in more than 50% of women. Many studies have suggested that underlying bleeding disorders are prevalent in menorrhagic women. However, the assessment and quantifying of hemorrhagic symptoms are still limited and not widely used. Thirty women aged 11-31 years with a clinical diagnosis of unexplained menorrhagia were investigated to assess the diagnostic utility of the condensed MCMDM-1VWD bleeding questionnaire as a predictive of bleeding disorders in these women. In addition to administration of the questionnaire, comprehensive hemostatic testing was performed to all women. The incidence of inherited bleeding disorders among this group was 66.6% (20/30). Eight patients had von Willebrand disease (VWD) and seven had possible Glanzmann's thrombasthenia. Rare bleeding disorders including hemophilia A carrier, Afibrinogenemia, Factor V deficiency and combined factor V and factor VIII deficiency were also identified. The receiver operator characteristic analysis of the condensed MCMDM-1 VWD bleeding questionnaire in menorrhagic women showed that the cutoff, sensitivity, specificity, positive and negative predictive values were 3.5, 85, 90, 89 and 86%, respectively. Bleeding score was strongly correlated to bleeding time in women with possible Glanzmann's thrombasthenia. In VWD, a significant inverse correlation between the bleeding score and the VW factor levels was detected with a significant increase of bleeding score in type III VWD compared with type I. Bleeding disorders are common in women with unexplained menorrhagia and the condensed MCMDM-1VWD bleeding questionnaire can distinguish between menorrhagic women with and without bleeding disorders and help assess their severity. Blood Coagul Fibrinolysis 23:311-315 ß 2012 Wolters Kluwer Health | Lippincott Williams & Wilkins.
Introduction
Menorrhagia is a common problem among women of reproductive age [1] . Approximately 30% of women complain of heavy menses [1, 2] and only 5% of women seek medical care for excessive menstrual bleeding [3, 4] . In approximately 50% of cases, menorrhagia cannot be explained by an organic disorder [1, 5] . Recent studies suggest that underlying bleeding disorders are common in this population [3, [6] [7] [8] . Von Willebrand's disease (VWD) is reported to have a prevalence in the general population of approximately 1% [9] . The prevalence of VWD in women presenting with menorrhagia ranges between 10 and 20% in Caucasian women, with a lower (1-2%) prevalence in African-American women [3, 8, 10, 11] . In addition, platelet function defects are reported to be the second common cause of bleeding disorders in women presenting with menorrhagia [8, 12] . Single coagulation factor deficiencies have also been reported, although at lower frequency than VWD and platelet function defects [3, 6, 8, 12] .
Referring all women with menorrhagia for hemostatic testing would be problematic for both patients and physicians, thus, many attempts at standardizing bleeding histories have been made in an effort to both prevent unwarranted laboratory testing and to prevent falsepositive diagnosis. The quantitative bleeding questionnaire was developed and validated by a group of investigators in Vicenza, Italy [13] . This detailed questionnaire is 17 pages long and takes 40 min to administer. Bleeding symptoms are scored from 0 (absence or trivial symptoms) to 3 (symptom requiring medical intervention).
In order to improve the sensitivity and specificity of the bleeding score, this scoring system was later revised to increase the range of possible grades from 1 (absence of bleeding after significant hemostatic challenge) to 4 (symptoms requiring the most significant medical intervention such as blood transfusion or replacement therapy). This bleeding score (http://www.shef.ac.uk/ euvwd/bleedscore.htm) was used for the European MCMDM-1VWD study and discriminated effectively between type I VWD and unaffected individuals [14] . Bowman et al. [15] have condensed this version of the questionnaire by maintaining only the details that directly affect the bleeding score resulting in a six-page questionnaire that can be administered in 5-10 min.
The present study was conducted to assess the diagnostic utility of the condensed MCMDM-1VWD bleeding questionnaire as a predictive of bleeding disorders in women with unexplained menorrhagia.
Materials and methods

Patients, inclusion and exclusion criteria
Thirty women aged 11-31 years with a clinical diagnosis of menorrhagia defined as prolonged (lasting more than 7 days) or excessive uterine bleeding occurring at regular intervals [16, 17] were referred from the primary care gynecology and clinical hematology outpatient clinics of Mansoura University Hospitals during the period between May 2010 and April 2011. A pelvic examination by a gynecologist was required for all women 19 years or older. Informed consent and ethics approval was obtained prior to the study according to Mansoura university guidelines.
Ninety women were excluded from participation before consent and study entry due to other known causes of heavy menstrual bleeding such as previously diagnosed bleeding disorders or endocrine disorders including thyroid disease, gynecological diseases such as submucous uterine myoma, uterine polyps, or gynecologic malignancy, and participants using intrauterine devices, or oral contraceptives within one cycle of participation, or nonsteroidal anti-inflammatory agents, aspirin, other platelets-impairing medications, anticoagulants within 2 months prior to the study or herbal agents within 14 days of participation to avoid potential interference with hemostatic testing.
Bleeding questionnaire
The condensed MCMDM-1VWD bleeding questionnaire [15] was administered for all 30 women and bleeding score was subsequently calculated.
Laboratory analysis
Blood sampling Two blood samples were collected (on the same day that the questionnaire was administered) in 3.2% sodium citrate (9 : 1 blood anticoagulant ratio) and in Ethylenediaminetetraacetic acid (EDTA). The citrated samples were spun at 150-200 g for 10 min to obtain the plateletrich plasma and used for platelet aggregation tests and then further spun at 2000 g for 10 min to obtain the platelet-poor plasma to be used for coagulation factor assay. EDTA blood samples were used for complete blood picture analysis including platelet count. ABO blood grouping were identified by using column agglutination technique (Diamed ID).
Basic screening tests
Bleeding time was performed at the time of sampling using a simplate device (Organon-Technica, Durham, North Carolina, USA) and a modified Ivy technique. Prothrombin time (PT) was performed using Thromborel S (SIEMENS, Marburg, Germany). Activated partial thromboplastin time (APTT) was performed using pathromtin SL (SIEMENS). Thrombin time (TT) (Clauss method) was performed using Multifibrin-u (SIE-MENS). Clot solubility test using 5 mol/l urea for factor XIII screening.
Coagulation factor assay
Depending on the results obtained from the above tests, coagulation factors II, V, VII, VIII, IX, X, XI activity were measured using factor deficient plasmas (SIEMENS). Fibrinogen antigen concentration is determined by (ELISA) technique. All coagulation tests were performed on an automated analyzer (CA-500 Sysmex; SIEMENS).
Platelet aggregation
Platelet aggregation was performed at 378 using platelet rich plasma in an optical chronolog platelet lumi-aggregometer (Chronolog Crop., Haverton, Pennsylvania, USA). Platelet agonists (Chronlog Corp.) used and their final concentrations were ADP (10, 5 and 2 mmol/l), ristocetin (1.25 and 0.5 mg/ml) and collagen (2 mg/ml).
Von Willebrand disease screen
Von Willebrand factor antigen (VWF : Ag) was measured by ELISA technique (REAADS, USA). Ristocetin cofactor activity (RCO) (VWF : RCO) was measured by agglutination of lyophilized normal platelets by ristocetin (SIEMENS). Factor VIII activity and ristocetin-induced platelet aggregation (RIPA) were measured as described above.
The laboratory quality controls for hemostatic tests
The quality controls used in coagulation factor measurements are as follows: Platelet aggregation testing was measured according to the standard guidelines [18, 19] .
Diagnosis and classification of bleeding disorders
Patients were classified as having coagulation factor deficiencies if a plasma clotting factor activity was less than 35%. Patients were classified as having a platelet function defect if the bleeding time was prolonged (>9 min) and the platelet aggregation was decreased in response to one or more platelet agonists below 2 SD of the normal laboratory range.
Possible Glanzmann's thrombathenia was diagnosed by prolonged bleeding time and severe reduction or no platelet aggregation with all agonists except reduced or normal aggregation with ristocetin.
The diagnosis of VWD was made if two or more tests were abnormal (VWF : RCO and/or VWF : Ag below 50% on at least two occasions, 3 weeks apart). For type I VWD, VWF : Ag and VWF:RCO were between 5 and 50% and VWF:RCO : Ag ratio was more than 0.6, whereas type II VWF:RCO : Ag ratio was less than 0.60. For type III VWD, if VWF : Ag and VWF : RCO were less than 5% and factor VIII: C was less than 10% [15] .
Statistical analysis
The analysis of data was carried out using SPSS (Statistical package for social science) program version 16 (SPSS, Inc, Chicago, Illinois, USA). Quantitative data was described as mean (AESD) and frequency and proportion were used for qualitative description. Student's ttest was used to compare parametric quantitative variables of two groups. Correlation coefficiency was performed to evaluate the association between variables. Pvalue was considered significant if less than 0.05 at confidence interval 95%. The sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV) of the bleeding score were calculated by using the receiver operator characteristic (ROC) curve.
Results
Thirty women diagnosed with unexplained menorrhagia comprised the study population. The mean and median ages of the study group were 20.2 þ 5.5 years and 20 years (minimum age, 11 years; maximum, 31 years), respectively.
Twenty out of our 30 participants (66.6%) were found to have one or more hemostatic abnormalities based on our laboratory analysis, seven of them were adolescents (<19 years). Of the 20 women, eight had VWD (three had positive family history), seven had positive Glanzmann's thrombathenia (two had positive family history), two were hemophilia A carriers (brothers of the two participants have been already diagnosed with hemophilia A) and three had rare coagulation factor deficiencies. Table 1 shows the details of these disorders.
The comparison of menorrhagic women with a bleeding disorder to those without a bleeding disorder revealed a significant increase in age, bleeding score, bleeding time and APTT and a significant decrease in factor VIII activity, VWF : Ag and VWF : RCO ( Table 2) .
Analysis of the condensed MCMDM-1VWD bleeding questionnaire in women with menorrhagia showed that the cutoff, sensitivity, specificity, accuracy, PPV and NPV of bleeding score were 3.5, 85, 90, 88, 89 and 86%, respectively. The ROC analysis showed area under the curve of 0.910 (P < 0.001). There was a strong positive correlation between the bleeding score and the bleeding time in women with possible Glanzmann's thrombasthenia (Pearson's correlation 0.924, P ¼ 0.003). In women with VWD, there was a significant inverse correlation between the bleeding score and the VWF : Ag and factor VIII activity (Pearson's correlation À0.69, À0.79, P < 0.05, P ¼ 0.02, respectively).
In this study, our laboratory results revealed eight menorrhagic women with the diagnosis of VWD (26.7%), five of them were classified as type I (three women with low VWF : Ag and VWF : RCO, two women with low VWF : Ag, VWF : RCO and RIPA) and three were diagnosed as type III. We found a significant increase in bleeding score in type III VWD when compared with type I (P ¼ 0.002).
Discussion
This study demonstrates that underlying hemostatic defects occur in the majority of women with unexplained menorrhagia. We found that 66.6% (20/30) of studied women with menorrhagia had two or more hemostatic defects. Our results are consistent with previous studies that have reported a substantial number of women with unexplained menorrhagia to have bleeding disorders [3, 6, 7] . However, we acknowledge the fact that our study showed higher rate of bleeding disorders in this population compared with previous studies and we believe this is partly due to the small sample size and possibly the high rate of consanguineous marriages in the Egyptian population.
A wide spectrum of bleeding disorders was obtained in our study. Although the majority were VWD (26.7%) and possible Glanzmann's thrombasthenia (23.3%), rare coagulation factor deficiencies such as carrier of hemophilia A (6.7%), afibrinogenemia (3.3%), factor V deficiency (3.3%) and combined factor V and factor VIII deficiency (3.3%) were also detected.
Women with unexplained menorrhagia Azzam et al. 313 However, defects in fibrinolysis are indeed not detected in this study. It has been suggested that a state of increased local fibrinolytic activity in the uterus may be a possible cause of functional menorrhagia [20] . Alternatively, both menorrhagia and increased local fibrinolytic activity may originate from a common mechanism such as increased vascularity of the uterus or altered activity of steroid hormones.
The age of women in this study ranged from 11 to 31 years including 14 adolescent women (<19 years). There was significant increase in the age among menorrhagic women with a bleeding disorder compared with those without a bleeding disorder (P ¼ 0.01). The 14 adolescent group comprized seven of 20 women with bleeding disorders. Of these, four had type I VWD, two had possible Glanzmann's thrombasthenia and one had combined factor V and factor VIII deficiency. The remaining seven did not have bleeding disorders. These results demonstrate that, although up to 50% of teens are anovulatory up to 5 years after menarche [21] , the underlying bleeding disorders were frequent in adolescent and reproductive age women presenting with menorrhagia and suggest that women with menorrhagia should be considered for further hemostatic evaluation. Our results coincides with that of Philipp et al. [22] , who have reported that adolescent women with menorrhagia were just as likely to have hemostatic abnormalities as were women aged 20-44 years.
Eight menorrhagic women had VWD (26.7%), five of them had type I and three had type III. VWD is extremely heterogeneous in its severity, ranging from mild bleeding manifestations to severe hemorrhagic episodes. The milder forms of VWD (type I and Type II) are often missed on diagnosis or may not be detected at all as screening coagulation tests may be in the normal range. Hence, in cases of suspected VWD or any other bleeding disorders, the patient should be investigated on at least two occasions.
In this study we have assessed the diagnostic utility of the condensed MCMDM-1VWD bleeding questionnaire as a predictive of bleeding disorders in women with unexplained menorrhagia. Bleeding score was significantly increased in menorrhagic women with a bleeding disorder (P < 0.001). Also, the ROC analysis showed an area under the curve of 0.910 (P < 0.001) and the bleeding score had 90% specifity and 85% sensitivity, which means that the questionnaire can distinguish between menorrhagic women with and without a bleeding disorder. The bleeding score was found to correlate directly with bleeding time in women with possible Glanzmann's thrombasthenia and indirectly with VWF : Ag and factor VIII activity in women with VWD. Also, the score can differentiate between type III and type I VWD.
Although there is some discussion about the real sensitivity and specificity of the bleeding score, we found this approach of real help, particularly because it forces both physicians and women to more objectively. However, we should use them with awareness of their limitations until full validation is performed by ongoing studies.
In conclusion, the bleeding disorders are frequently found in women presenting with unexplained menorrhagia and suggest that adolescent and reproductive age women with menorrhagia should be considered for further hemostatic evaluation. Also, the condensed MCMDM-1VWD bleeding questionnaire as a standardized bleeding score is potentially useful to distinguish between menorrhagic women with and without a bleeding disorder and in VWD, correlates with VWF levels and can help assess the severity of the disease. 
